Cargando…
Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: A case report and literature review
The benefit of immunochemotherapy in treating resectable locally advanced non-small cell lung cancer (NSCLC) is not well established. Here, we report a case of resectable stage III NSCLC treated with neoadjuvant immunotherapy combined with chemotherapy before surgery. A 61 years old man was admitted...
Autores principales: | Zheng, Yuan, Zhu, Wei, Huang, Xinjie, Lin, Dongqun, Lin, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389505/ https://www.ncbi.nlm.nih.gov/pubmed/34514162 http://dx.doi.org/10.1515/biol-2021-0083 |
Ejemplares similares
-
Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021) -
Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021) -
Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study
por: Zhang, Hai, et al.
Publicado: (2023) -
Neoadjuvant immunotherapy combined with chemotherapy in the treatment of stage III lung squamous cell carcinoma: a retrospective cohort study
por: Guo, Jing, et al.
Publicado: (2023) -
Neoadjuvant Immunotherapy Combined Chemotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study
por: Hong, Zhi-Nuan, et al.
Publicado: (2021)